Dihlmann et al. reported that after adjusting for clinicopathological characteristics, complete lack of AIM2 expression was associated with significantly increased overall and disease-specific mortality compared to AIM2-positive tumor samples, suggesting that lack of AIM2 expression is strongly related to poor outcomes in CRC. Here, AIM2 is linked to colorectal carcinoma.